Cocrystal Pharma, Inc.今日宣布,其评估CDI-988用于诺如病毒预防与治疗的1B期人体挑战试验,已完成最后一名受试者的给药。此举标志着该临床试验进入关键节点,为这一候选抗病毒药物的后续数据读出奠定了基础。
Cocrystal Pharma, Inc.今日宣布,其评估CDI-988用于诺如病毒预防与治疗的1B期人体挑战试验,已完成最后一名受试者的给药。此举标志着该临床试验进入关键节点,为这一候选抗病毒药物的后续数据读出奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.